Keyword: Insys Therapeutics
The U.S. Senate has released a report on Insys that provides an insider’s view of a company leaning on physicians to help drive sales.
The $150 million is in line with Insys' previous estimate, and the final deal could include contingency-based payments of up to $75 million.
Doctors who got free meals, speaking fees and other payments from drugmakers also prescribed more opioids, a new analysis found.
Newly unsealed court documents allege Insys provided incentives for off-label prescribing of its painkiller Subsys.
The feds charged five doctors over accepting Insys' bribes and said they've secured cooperation from two former employees.
In what may be the first foray by Big Pharma into the sale of medical marijuana products, Novartis has struck a deal with a Canadian company that sells medical cannabis products.
Drugmakers contributed more than $10 million to organizations and affiliated individuals that backed wide opioid use, a senator's investigation found.
Lawyers for former Insys sales executive Jeffrey Pearlman asked the court to censure the term "opioid crisis" during his kickbacks trial.
On the heels of the high-profile arrest of Insys' billionaire founder John Kapoor, the drugmaker has recorded a $150 million charge.
Federal agents arrested Insys founder John Kapoor and charged him with racketeering and other felonies.